Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups

U. Creutzig, MN. Dworzak, M. Zimmermann, D. Reinhardt, L. Sramkova, JP. Bourquin, H. Hasle, J. Abrahamsson, G. Kaspers, MM. van den Heuvel, AMJ. Reedijk, B. De Moerloose, F. Locatelli, R. Masetti,

. 2017 ; 64 (12) : . [pub] 20170609

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016558

BACKGROUND: There is no consensus on the treatment for pediatric patients with acute myeloid leukemia and initial central nervous system (CNS) involvement. METHODS: To evaluate different CNS-directed treatment options (intrathecal [IT] therapy, CNS irradiation, hematopoietic stem cell transplantation [HSCT]), 261 patients (excluding acute promyelocytic leukemia) with initial CNS involvement treated in trials with similar intensive chemotherapy by four cooperative European study groups (1998-2013) were studied and compared with CNS-negative patients from the Berlin-Frankfurt-Münster group. RESULTS: Patient characteristics in the different study groups were comparable. Young age, high white blood cell count, extramedullary involvement other than the CNS, monoblastic morphology, and inv(16) were associated with CNS involvement (each P < 0.0001). There were no major differences in outcome between the study groups. The cumulative incidence of relapse (CIR) regarding the CNS was higher in initially CNS-positive versus initially CNS-negative patients (all: 8 ± 2% vs. 3 ± 1%, P(Gray) = 0.001; isolated: 4 ± 1% vs. 1 ± 0%, P(Gray) = 0.03). However, global outcome of the CNS-positive cohort (overall survival, 64 ± 3%; event-free survival 48 ± 3%; and CIR 33% ± 3%) did not differ significantly from CNS-negative patients. Risk groups defined by cytogenetics were of likewise prognostic significance in CNS-positive and -negative patients. CNS treatment with cranial irradiation was not superior compared to IT therapy and systemic chemotherapy (± HSCT). CONCLUSION: Although CNS relapses occurred more frequently in initially CNS-positive patients, their global outcome was similar as in CNS-negative patients. Intensified IT therapy was heterogeneous; however, at least eight applications, preferably with triple IT chemotherapy, seem to be appropriate to accompany dose-intensive systemic chemotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016558
003      
CZ-PrNML
005      
20180518095718.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.26664 $2 doi
035    __
$a (PubMed)28598536
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Creutzig, Ursula $u Department of Pediatric Hematology and Oncology, Children's Hospital, Hannover Medical School, Hannover, Germany.
245    10
$a Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups / $c U. Creutzig, MN. Dworzak, M. Zimmermann, D. Reinhardt, L. Sramkova, JP. Bourquin, H. Hasle, J. Abrahamsson, G. Kaspers, MM. van den Heuvel, AMJ. Reedijk, B. De Moerloose, F. Locatelli, R. Masetti,
520    9_
$a BACKGROUND: There is no consensus on the treatment for pediatric patients with acute myeloid leukemia and initial central nervous system (CNS) involvement. METHODS: To evaluate different CNS-directed treatment options (intrathecal [IT] therapy, CNS irradiation, hematopoietic stem cell transplantation [HSCT]), 261 patients (excluding acute promyelocytic leukemia) with initial CNS involvement treated in trials with similar intensive chemotherapy by four cooperative European study groups (1998-2013) were studied and compared with CNS-negative patients from the Berlin-Frankfurt-Münster group. RESULTS: Patient characteristics in the different study groups were comparable. Young age, high white blood cell count, extramedullary involvement other than the CNS, monoblastic morphology, and inv(16) were associated with CNS involvement (each P < 0.0001). There were no major differences in outcome between the study groups. The cumulative incidence of relapse (CIR) regarding the CNS was higher in initially CNS-positive versus initially CNS-negative patients (all: 8 ± 2% vs. 3 ± 1%, P(Gray) = 0.001; isolated: 4 ± 1% vs. 1 ± 0%, P(Gray) = 0.03). However, global outcome of the CNS-positive cohort (overall survival, 64 ± 3%; event-free survival 48 ± 3%; and CIR 33% ± 3%) did not differ significantly from CNS-negative patients. Risk groups defined by cytogenetics were of likewise prognostic significance in CNS-positive and -negative patients. CNS treatment with cranial irradiation was not superior compared to IT therapy and systemic chemotherapy (± HSCT). CONCLUSION: Although CNS relapses occurred more frequently in initially CNS-positive patients, their global outcome was similar as in CNS-negative patients. Intensified IT therapy was heterogeneous; however, at least eight applications, preferably with triple IT chemotherapy, seem to be appropriate to accompany dose-intensive systemic chemotherapy.
650    _2
$a mladiství $7 D000293
650    _2
$a nádory centrálního nervového systému $x mortalita $x terapie $7 D016543
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kraniální ozáření $7 D016371
650    _2
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a akutní myeloidní leukemie $x mortalita $x terapie $7 D015470
650    _2
$a sekundární malignity $x epidemiologie $7 D016609
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a recidiva $7 D012008
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dworzak, Michael N $u Department of Pediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria.
700    1_
$a Zimmermann, Martin $u Department of Pediatric Hematology and Oncology, Children's Hospital, Hannover Medical School, Hannover, Germany.
700    1_
$a Reinhardt, Dirk $u Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
700    1_
$a Sramkova, Lucie $u Department of Pediatric Hematology and Oncology, Charles University Prague, Czech Pediatric Hematology Working Group (CPH), Prague, Czech Republic.
700    1_
$a Bourquin, Jan Pierre $u Department of Pediatric Hematology/Oncology, University of Zurich, Zurich, Switzerland.
700    1_
$a Hasle, Henrik $u Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark.
700    1_
$a Abrahamsson, Jonas $u Department of Pediatrics, Institution of Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden.
700    1_
$a Kaspers, Gertjan $u Pediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands. Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands.
700    1_
$a van den Heuvel, Mary M $u Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands. Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
700    1_
$a Reedijk, Ardine M J $u Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands.
700    1_
$a De Moerloose, Barbara $u Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
700    1_
$a Locatelli, Franco $u Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, University of Pavia, Rome, Italy.
700    1_
$a Masetti, Riccardo $u Oncologia ed Ematologia Pediatrica "Lalla Seràgnoli" Ospedale Sant'Orsola Malpighi Università di Bologna, Bologna, Italy.
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 64, č. 12 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28598536 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180518095856 $b ABA008
999    __
$a ok $b bmc $g 1300182 $s 1013398
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 64 $c 12 $e 20170609 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace